Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... be offering campers a multitude of activities from daily practices, arts & crafts, ... , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, ... the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led ... professional through the 8 hour interactive course to qualify participants as certified PowerWave ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that doesn't sacrifice taste? ... has ignited an undeniable buzz in the protein product community by offering an alternative ... These doughnuts are packed with 11 grams of protein and made from a healthy ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
(Date:5/24/2016)... Niederländische Chirurgen haben eine ... Ärzten erlaubt, ihre Expertise weltweit zu teilen und ... Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, in ... Europa, Afrika, Asien und den USA ... registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: